A Pilot Study of MRI [magnetic resonance imaging] and Spectroscopy Imaging Changes With 6-Months of Dutasteride in Patients With Symptomatic Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer on Watchful Waiting or Requiring Neoadjuvant Androgen Suppression Prior to Prostate Brachytherapy.
Phase of Trial: Phase IV
Latest Information Update: 21 Oct 2013
At a glance
- Drugs Dutasteride (Primary)
- Indications Benign prostatic hyperplasia; Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 24 Jul 2008 New trial record.